117 related articles for article (PubMed ID: 19361602)
1. Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Andreadou I; Ikonomidis I; Markantonis S; Ioannidis K; Paraskevaidis I; Iliodromitis E; Filippatos G; Kremastinos DT
Am J Cardiol; 2009 Apr; 103(8):1134-8. PubMed ID: 19361602
[TBL] [Abstract][Full Text] [Related]
2. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
[TBL] [Abstract][Full Text] [Related]
3. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
[TBL] [Abstract][Full Text] [Related]
4. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
[TBL] [Abstract][Full Text] [Related]
5. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure.
Kourea K; Parissis JT; Farmakis D; Panou F; Paraskevaidis I; Venetsanou K; Filippatos G; Kremastinos DT
Atherosclerosis; 2008 Jul; 199(1):215-21. PubMed ID: 17991471
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
9. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
11. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure.
Parissis JT; Andreadou I; Markantonis SL; Bistola V; Louka A; Pyriochou A; Paraskevaidis I; Filippatos G; Iliodromitis EK; Kremastinos DT
Atherosclerosis; 2007 Dec; 195(2):e210-5. PubMed ID: 17707851
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
14. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
Palazzuoli A; Silverberg DS; Calabrò A; Spinelli T; Quatrini I; Campagna MS; Franci B; Nuti R
J Cardiovasc Pharmacol; 2009 Jun; 53(6):462-7. PubMed ID: 19455052
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
17. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
